UNSPSC 51162034: Guaifenesin/theophylline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162034 Guaifenesin/theophylline is a Commodity code tracking pharmaceutical products, though recent state and local opportunities show significant mismatch with the code's nominal scope—actual solicitations name naloxone, drug deactivation systems, and on-site pharmacy services across multiple therapeutic categories rather than the specific bronchodilator-expectorant combination the code describes. State and local issuing bodies using this code include county health departments and county government employee health programs. Seminole County, Florida and Hall County, Georgia represent the recent activity visible in the data, both pursuing health-system support through pharmaceutical procurement rather than purchases of a single named drug product.

Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023, and a potential two-year initial term plus one-year renewal option. Hall County, Georgia issued RFQ/P #47-010 in May 2026 seeking an on-site pharmacy services provider to serve approximately 3,005 eligible county employees, retirees, and dependents through the Hall County Government Family Health Center Clinic in Gainesville, with evaluation weighted 80% on technical qualifications and 20% on cost, a response deadline of June 4, 2026, and a one-year initial term with four optional one-year renewals. The code shows little recent activity aligned with its stated pharmaceutical scope; procurement under this classification appears to reflect broader health-system purchasing rather than targeted demand for guaifenesin/theophylline formulations.